European guidance for the diagnosis and management of osteoporosis in postmenopausal women

J A Kanis, E V McCloskey, H Johansson, C Cooper, R Rizzoli, J-Y Reginster, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF), J A Kanis, E V McCloskey, H Johansson, C Cooper, R Rizzoli, J-Y Reginster, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF)

Abstract

Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.

Introduction: The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2008. This manuscript updates these in a European setting.

Methods: Systematic literature reviews.

Results: The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk, general and pharmacological management of osteoporosis, monitoring of treatment, assessment of fracture risk, case finding strategies, investigation of patients and health economics of treatment.

Conclusions: A platform is provided on which specific guidelines can be developed for national use.

Figures

Fig. 1
Fig. 1
Ten-year probability of hip fracture in women from Sweden according to age and T-score for femoral neck BMD [52] with kind permission from Springer Science and Business Media
Fig. 2
Fig. 2
Screen page for input of data and format of results in the UK version of the FRAX® tool (UK model, version 3.5. http://www.shef.ac.uk/FRAX) [With permission of the World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK]
Fig. 3
Fig. 3
Ten year probability (in percent) of a hip fracture in women from different European countries. BMI set to 24 kg/m2
Fig. 4
Fig. 4
Management algorithm for the assessment of individuals at risk of fracture [89] with kind permission from Springer Science and Business Media
Fig. 5
Fig. 5
The 10-year probability of a major osteoporotic fracture by age in women with a prior fracture and no other clinical risk factors in the five major EU countries as determined with FRAX (version 3.5). Body mass index was set to 24 kg/m2 without BMD
Fig. 6
Fig. 6
The density of central DXA equipment (units per million of the general population in the EU countries in 2010 [Kanis JA, data on file])
Fig. 7
Fig. 7
Assessment of fracture risk in countries with high access to DXA. DXA is undertaken in women with a clinical risk factor. Assessment with DXA and/or treatment is not recommended where the FRAX probability is lower than the lower assessment threshold (green area). BMD is recommended in other women and treatment recommended where the fracture probability exceeds the intervention threshold (dotted line). The intervention threshold used is that derived from Table 7
Fig. 8
Fig. 8
Assessment guidelines based on the 10-year probability of a major fracture (in percent). The dotted line denotes the intervention threshold. Where assessment is made in the absence of BMD, a BMD test is recommended for individuals where the probability assessment lies in the orange region. The intervention threshold and BMD assessment thresholds used are those derived from Table 7
Fig. 9
Fig. 9
The impact of a fixed treatment threshold in postmenopausal women in the UK according to threshold values for the probability of a major fracture. The left-hand panel shows the proportion of the postmenopausal population exceeding the threshold shown at each age. The right-hand panel shows the proportion of the total postmenopausal population that exceeds a given threshold
Fig. 10
Fig. 10
The risk of hip fracture with age in a model that considers 10-year fracture risk alone (the Garvan tool) and FRAX which computes the probability of hip fracture from the fracture and death hazards (FRAX). The T-scores are set differently in the two models so that the risks are approximately equal at the age of 60 years. Data are computed from the respective websites [127]. With kind permission from Springer Science and Business Media
Fig. 11
Fig. 11
Correlation between the 10-year probability of a major fracture (calculated with BMD) and cost-effectiveness of generic alendronate at the age of 50 years in women. Each point represents a particular combination of BMD and clinical risk factors (all possible combinations of CRFs at BMD T-scores between 0 and −3.5 SD in 0.5 SD steps—512 combinations) with a BMI set to 26 kg/m2. The horizontal line denotes the threshold for cost-effectiveness (a willingness to pay of £20,000/QALY gained) ([122], with permission from Elsevier)

References

    1. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7:390–406. doi: 10.1007/BF01623782.
    1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399–428. doi: 10.1007/s00198-008-0560-z.
    1. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767–778. doi: 10.1007/s00198-004-1675-5.
    1. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35:293–305. doi: 10.1016/j.semarthrit.2005.11.001.
    1. Haaland DA, Cohen DR, Kennedy CC, Khalidi NA, Adachi JD, Papaioannou A. Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr. 2009;9:28. doi: 10.1186/1471-2318-9-28.
    1. Consensus Development Conference Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646–650. doi: 10.1016/0002-9343(93)90218-E.
    1. World Health Organisation Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
    1. Kanis JA, on behalf of the WHO Scientific Group . Assessment of osteoporosis at the primary health-care level. Technical Report. UK: WHO Collaborating Centre, University of Sheffield; 2008.
    1. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111–1115. doi: 10.1136/bmj.307.6912.1111.
    1. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11:669–674. doi: 10.1007/s001980070064.
    1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733. doi: 10.1007/s00198-006-0172-4.
    1. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N. Assessment of fracture risk. Osteoporos Int. 2005;16:581–589. doi: 10.1007/s00198-004-1780-5.
    1. Strom O, Borgstrom F, Kanis JA, Compston JE, Cooper C, McCloskey E, Jonsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos doi:10.1007/s11657-011-0060-1
    1. Kanis JA, Compston J, Cooper C, et al. The burden of fractures in the European Union in 2010. Osteoporos Int. 2012;23(Suppl 2):S57.
    1. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ., 3rd Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001–1005.
    1. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003;32:468–473. doi: 10.1016/S8756-3282(03)00061-9.
    1. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007;10:102–110. doi: 10.1016/j.jocd.2006.11.001.
    1. Engelke K, Gluer CC. Quality and performance measures in bone densitometry: part 1: errors and diagnosis. Osteoporos Int. 2006;17:1283–1292. doi: 10.1007/s00198-005-0039-0.
    1. Gluer CC, Lu Y, Engelke K. Quality and performance measures in bone densitometry. Part 2: fracture risk. Osteoporos Int. 2006;17:1449–1458. doi: 10.1007/s00198-005-0038-1.
    1. Ranjanomennahary P, Ghalila SS, Malouche D, Marchadier A, Rachidi M, Benhamou C, Chappard C. Comparison of radiograph-based texture analysis and bone mineral density with three-dimensional microarchitecture of trabecular bone. Med Phys. 2011;38:420–428. doi: 10.1118/1.3528125.
    1. Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, Lespessailles E, Benhamou CL, Miossec P, Chapurlat R. Assessment of hand trabecular bone texture with high resolution direct digital radiograph in rheumatoid arthritis: a case control study. Joint Bone Spine. 2011;79:379–383. doi: 10.1016/j.jbspin.2011.09.012.
    1. Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26:2762–2769. doi: 10.1002/jbmr.499.
    1. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom. 2011;14:302–312. doi: 10.1016/j.jocd.2011.05.005.
    1. Genant HK, Lang TF, Engelke K, Fuerst T, Gluer C, Majumdar S, Jergas M. Advances in the noninvasive assessment of bone density, quality, and structure. Calcif Tissue Int. 1996;59(Suppl 1):S10–S15. doi: 10.1007/s002239900169.
    1. Mazess RB, Collick B, Trempe J, Barden H, Hanson J. Performance evaluation of a dual energy x-ray bone densitometer. Calcif Tissue Int. 1998;44:228–232. doi: 10.1007/BF02556569.
    1. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ., 3rd Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int. 2005;16:1883–1893. doi: 10.1007/s00198-005-1956-7.
    1. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ., 3rd Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score >-2.5 for alendronate therapy: a modeling study. J Clin Densitom. 2006;9:133–143. doi: 10.1016/j.jocd.2005.11.004.
    1. Vokes T, Bachman D, Baim S, Binkley N, Broy S, Ferrar L, Lewiecki EM, Richmond B, Schousboe J. Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9:37–46. doi: 10.1016/j.jocd.2006.05.006.
    1. Ferrar L, Jiang G, Schousboe JT, DeBold CR, Eastell R. Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches. J Bone Miner Res. 2008;23:417–424. doi: 10.1359/jbmr.071032.
    1. McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A, Bonnet N, Beneton M, Kanis JA, Charlesworth D. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res. 2008;23:1561–1568. doi: 10.1359/jbmr.080515.
    1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259. doi: 10.1136/bmj.312.7041.1254.
    1. Gluer CC. Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res. 1997;12:1280–1288. doi: 10.1359/jbmr.1997.12.8.1280.
    1. Watts NB. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA) Osteoporos Int. 2004;15:847–854. doi: 10.1007/s00198-004-1681-7.
    1. Kanis JA, Melton LJ, 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141. doi: 10.1002/jbmr.5650090802.
    1. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42:467–475. doi: 10.1016/j.bone.2007.11.001.
    1. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int. 2000;11:192–202. doi: 10.1007/s001980050281.
    1. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC, Jr, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8:468–489. doi: 10.1007/s001980050093.
    1. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194. doi: 10.1359/JBMR.050304.
    1. De Laet CEDH, Van Hout BA, Burger H, Hofman A, Weel AE, Pols H. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res. 1998;13:1587–1593. doi: 10.1359/jbmr.1998.13.10.1587.
    1. Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, Seeman E. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789–2798. doi: 10.1007/s00198-011-1632-z.
    1. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW., Jr Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab. 2004;89:3651–3655. doi: 10.1210/jc.2004-0124.
    1. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom. 2006;9:4–14. doi: 10.1016/j.jocd.2006.05.002.
    1. Blake GM, Patel R, Knapp KM, Fogelman I. Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res. 2003;18:1955–1963. doi: 10.1359/jbmr.2003.18.11.1955.
    1. Kanis JA, Johnell O, Oden A, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int. 2006;17:527–534. doi: 10.1007/s00198-005-0014-9.
    1. Leslie WD, Lix LM, Tsang JF, Caetano PA. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med. 2007;167:1641–1647. doi: 10.1001/archinte.167.15.1641.
    1. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone. 2000;27:585–590. doi: 10.1016/S8756-3282(00)00381-1.
    1. Osteoporosis: clinical guidelines for the prevention and treatment. London: RCP; 1999.
    1. Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. London: RCP; 2002.
    1. Clinician's guide to prevention and treatment of osteoporosis. Washington: NOF; 2008.
    1. NICE technology appraisal guidance 161 (amended). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) London: NICE; 2011.
    1. NICE technology appraisal guidance 160 (amended). Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended) London: NICE; 2011.
    1. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989–995. doi: 10.1007/s001980170006.
    1. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72–75. doi: 10.1016/0140-6736(93)92555-8.
    1. Moayyeri A, Adams JE, Adler RA, Krieg MA, Hans D, Compston J, Lewiecki EM. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. Osteoporos Int. 2012;23:143–153. doi: 10.1007/s00198-011-1817-5.
    1. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–773. doi: 10.1056/NEJM199503233321202.
    1. Ribot C, Pouilles JM, Bonneu M, Tremollieres F. Assessment of the risk of post-menopausal osteoporosis using clinical factors. Clin Endocrinol (Oxf) 1992;36:225–228. doi: 10.1111/j.1365-2265.1992.tb01436.x.
    1. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ., 3rd Predictors of hip fractures in elderly men. J Bone Miner Res. 1995;10:1900–1907. doi: 10.1002/jbmr.5650101209.
    1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–1936. doi: 10.1016/S0140-6736(02)08761-5.
    1. Hui SL, Slemenda CW, Johnston C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1998;81:1804–1809. doi: 10.1172/JCI113523.
    1. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:1029–1037. doi: 10.1016/j.bone.2004.06.017.
    1. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893–899. doi: 10.1359/JBMR.040134.
    1. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:737–742. doi: 10.1007/s00198-004-1734-y.
    1. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman J. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2006;16:155–162. doi: 10.1007/s00198-004-1640-3.
    1. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16:1330–1338. doi: 10.1007/s00198-005-1863-y.
    1. Klotzbuecher CM, Ross PD, Landsman PD, Abbott TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–739. doi: 10.1359/jbmr.2000.15.4.721.
    1. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX® with and without bone mineral density. Calcif Tissue Int. 2012;90:1–13. doi: 10.1007/s00223-011-9544-7.
    1. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305:2184–2192. doi: 10.1001/jama.2011.715.
    1. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27:301–308. doi: 10.1002/jbmr.556.
    1. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19:1431–1444. doi: 10.1007/s00198-008-0588-0.
    1. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229. doi: 10.1136/bmj.b4229.
    1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–340. doi: 10.1056/NEJM200102013440503.
    1. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2–S17. doi: 10.1007/s001980070002.
    1. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int. 2002;13:523–526. doi: 10.1007/s001980200068.
    1. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391–420. doi: 10.1007/s00198-010-1501-1.
    1. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–397. doi: 10.1007/s00198-007-0543-5.
    1. WHO (2007) Assessment of osteoporosis at the primary health care level. WHO, Geneva. At: . Accessed May 2012
    1. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046. doi: 10.1007/s00198-007-0343-y.
    1. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17:1237–1244. doi: 10.1359/jbmr.2002.17.7.1237.
    1. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22:2395–2411. doi: 10.1007/s00198-011-1713-z.
    1. Hans DB, Kanis JA, Baim S, et al. Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom. 2011;14:171–180. doi: 10.1016/j.jocd.2011.05.007.
    1. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000. doi: 10.1359/jbmr.2000.15.6.993.
    1. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:155–162. doi: 10.1007/s00198-004-1640-3.
    1. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809–816. doi: 10.1007/s00198-010-1524-7.
    1. Papaioannou A, Morin S, Cheung AM, et al. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182:1864–1873. doi: 10.1503/cmaj.100771.
    1. Orimo H, Nakamura T, Fukunaga M (2006) Japanese guidelines for the prevention and treatment of osteoporosis (Translated Abridged Edition)
    1. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM, Silverman S. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11:75–91. doi: 10.1016/j.jocd.2007.12.007.
    1. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22:839–847. doi: 10.1007/s00198-010-1461-5.
    1. Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM, Prior JC, Josse RG, Jamal SA, Kreiger N, Goltzman D. Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX®: a population-based report from CAMOS. J Clin Densitom. 2011;14:286–293. doi: 10.1016/j.jocd.2011.04.011.
    1. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395–1408. doi: 10.1007/s00198-008-0712-1.
    1. Kanis JA, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women—what is the current message for clinical practice? Pol Arch Med Wewn. 2008;118:538–540.
    1. Physician's guide to prevention and treatment of osteoporosis. Washington DC: NOF; 2003.
    1. Report on osteoporosis in the European Community. Strasbourg: EC; 1998.
    1. Brixen K (2002) Consensus report on osteoporosis. Ugeskr Laeger Suppl. 10
    1. Hellenic Foundation for Osteoporosis (2004) Kateufunthries gpammes gia th diagnwsh kai antimetwpisnh ths Osteopowshs sthn Ellada (Guidelines for diagnosis and management of osteoporosis in Greece). Athens
    1. Collegio dei Reumatologi Ospedalieri, Società Italiana dell'Osteoporosi e delle Malattie del Metabolismo Minerale e Scheletrico, Società Italiana di Medicina Fisica e Riabilitativa, Società Italiana di Medicina Interna, Società Italiana di Ortopedia e Traumatologia, Società Italiana di Radiologia Medica, Società Italiana di Reumatologia (2006) Linee guida per la diagnosi, prevenzione e terapia dell'osteoporosi (Guidelines for the diagnosis, prevention and treatment of osteoporosis). SINOSSI. EDIMES., Pavia
    1. Pols HA, Wittenberg J. CBO guideline 'Osteoporosis' (second revision] Ned Tijdschr Geneeskd. 2002;146:1359–1363.
    1. SEIOMM (2003) Guía de Práctica: osteoporosis posmenopáusica (Practice guidelines: postmenopausal osteoporosis). Revista Clinica Española. pp 496–506
    1. Management of osteoporosis. Edinburgh: SIGN; 2003.
    1. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008;93:2463–2465. doi: 10.1210/jc.2008-0926.
    1. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229–238. doi: 10.1007/s00198-004-1811-2.
    1. Association Suisse contre l‘Ostéoporose (2010) Ostéoporose: Recommandations 2010. ASCO. . Accessed May 2012
    1. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62:105–108. doi: 10.1016/j.maturitas.2008.11.022.
    1. Czerwinski E, Kanis JA, Trybulec B, Johansson H, Borowy P, Osieleniec J. The incidence and risk of hip fracture in Poland. Osteoporos Int. 2009;20:1363–1367. doi: 10.1007/s00198-008-0787-8.
    1. Badurski JE, Kanis JA, Johansson H, Dobrenko A, Nowak NA, Daniluk S, Jezienicka E. The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. Pol Arch Med Wewn. 2011;121:148–155.
    1. Dawson-Hughes B, Tosteson AN, Melton LJ, 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449–458. doi: 10.1007/s00198-008-0559-5.
    1. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX) Osteoporos Int. 2008;19:429–435. doi: 10.1007/s00198-007-0544-4.
    1. Grossman JM, Gordon R, Ranganath VK, American College of Rheumatology et al. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–1526. doi: 10.1002/acr.20295.
    1. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B. Intervention thresholds for osteoporosis. Bone. 2002;31:26–31. doi: 10.1016/S8756-3282(02)00813-X.
    1. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int. 2005;16:6–14. doi: 10.1007/s00198-004-1623-4.
    1. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone. 2005;36:22–32. doi: 10.1016/j.bone.2004.08.018.
    1. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (in press)
    1. Lippuner K, Johansson H, Kanis JA, Rizzoli R. FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int. 2010;21:381–389. doi: 10.1007/s00198-009-0975-1.
    1. Clinician's guide to prevention and treatment of osteoporosis. Washington DC: NOF; 2008.
    1. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyere O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY. A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege. 2009;64:612–619.
    1. Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010 - stöd för styrning och ledning. Preliminär version. Artikelnr 2010-11-15. Publicerad . Accessed June 2012
    1. Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012;79:304–313. doi: 10.1016/j.jbspin.2012.02.014.
    1. Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437–447. doi: 10.1007/s00198-007-0550-6.
    1. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11:1–256.
    1. Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA. Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res. 2004;19:906–913. doi: 10.1359/jbmr.2004.19.6.906.
    1. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int. 2009;20:1675–1682. doi: 10.1007/s00198-009-0845-x.
    1. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E. A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporos Int. 2012;23:907–915. doi: 10.1007/s00198-011-1864-y.
    1. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42:4–15. doi: 10.1016/j.bone.2007.10.019.
    1. Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012;23:75–85. doi: 10.1007/s00198-011-1747-2.
    1. Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int. 2012;23:391–397. doi: 10.1007/s00198-011-1592-3.
    1. Dachverband Osteologie e.V DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie. 2011;20:55–74.
    1. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ. 2011;342:d3651. doi: 10.1136/bmj.d3651.
    1. Kanis JA, Oden A, Johansson H, McCloskey E. Pitfalls in the external validation of FRAX. Osteoporos Int. 2012;23:423–431. doi: 10.1007/s00198-011-1846-0.
    1. Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC, Wells G, Tugwell P, Cranney A (2002) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333
    1. Howe TE, Rochester L, Neil F, Skelton DA, Ballinger C. Exercise for improving balance in older people. Cochrane Database Syst Rev. 2011;11:CD004963.
    1. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev CD000333
    1. Myers AH, Young Y, Langlois JA. Prevention of falls in the elderly. Bone. 1996;18:87S–101S. doi: 10.1016/8756-3282(95)00384-3.
    1. Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153:815–825.
    1. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008;56:2234–2243. doi: 10.1111/j.1532-5415.2008.02014.x.
    1. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet. 2005;366:1885–1893. doi: 10.1016/S0140-6736(05)67604-0.
    1. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334:82. doi: 10.1136/bmj.39049.706493.55.
    1. Gillespie WJ, Gillespie LD, Parker MJ (2010) Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev CD001255
    1. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, Cranney A, Zytaruk N, Hanley DA, Adachi JD. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2005;16:1461–1474. doi: 10.1007/s00198-005-1932-2.
    1. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ. 2006;332:571–574. doi: 10.1136/bmj.38753.375324.7C.
    1. Kiel DP, Magaziner J, Zimmerman S, Ball L, Barton BA, Brown KM, Stone JP, Dewkett D, Birge SJ. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA. 2007;298:413–422. doi: 10.1001/jama.298.4.413.
    1. Rizzoli R. Nutrition: its role in bone health. Best Pract Res Clin Endocrinol Metab. 2008;22:813–829. doi: 10.1016/j.beem.2008.08.005.
    1. Bonjour JP, Guéguen L, Palacios C, Shearer MJ, Weaver CM. Minerals and vitamins in bone health: the potential value of dietary enhancement. Br J Nutr. 2009;101:1581–1596. doi: 10.1017/S0007114509311721.
    1. Food and Agricultural Organization of the United Nations/World Health Organization (2001) Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation. Bangkok, Thailand. Washington, DC
    1. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370:657–666. doi: 10.1016/S0140-6736(07)61342-7.
    1. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692. doi: 10.1136/bmj.b3692.
    1. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women—a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007;46:1852–1857. doi: 10.1093/rheumatology/kem240.
    1. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303:1815–1822. doi: 10.1001/jama.2010.594.
    1. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152:315–323.
    1. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730–1737. doi: 10.1001/archinte.167.16.1730.
    1. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. doi: 10.1136/bmj.d2040.
    1. Bolland MJ, Grey A, Reid IR. Misclassification does not explain increased cardiovascular risks of calcium supplements. J Bone Miner Res. 2012;27:959. doi: 10.1002/jbmr.1568.
    1. Grey A, Bolland M, Reid R. Calcium supplements and cardiovascular disease—picking the spin. Int J Clin Pract. 2011;65:226–227. doi: 10.1111/j.1742-1241.2010.02557.x.
    1. Bolland MJ, Grey A, Reid IR. Re: the calcium scare: what would Austin Bradford Hill have thought? Osteoporos Int. 2011;22:3079–3080. doi: 10.1007/s00198-011-1783-y.
    1. Lewis JR, Zhu K, Prince RL. Response to: misclassification does not explain increased cardiovascular risks of calcium supplements. J Bone Miner Res. 2012;27:960–961. doi: 10.1002/jbmr.1569.
    1. Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012;27:719–722. doi: 10.1002/jbmr.1484.
    1. Nordin BE, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange K, Prince RL. The calcium scare—what would Austin Bradford Hill have thought? Osteoporos Int. 2011;22:3073–3077. doi: 10.1007/s00198-011-1680-4.
    1. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res. 2011;26:35–41. doi: 10.1002/jbmr.176.
    1. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841–847. doi: 10.1016/j.bone.2008.01.003.
    1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018–2026. doi: 10.1016/S0140-6736(02)08827-X.
    1. Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2005;16:239–254. doi: 10.1007/s00198-004-1812-1.
    1. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33:522–532. doi: 10.1016/S8756-3282(03)00241-2.
    1. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama. 1999;282:637–645. doi: 10.1001/jama.282.7.637.
    1. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama. 1999;281:2189–2197. doi: 10.1001/jama.281.23.2189.
    1. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama. 2006;295:2727–2741. doi: 10.1001/jama.295.23.joc60074.
    1. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. AmJ Cardiol. 2001;88:392–395. doi: 10.1016/S0002-9149(01)01685-X.
    1. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137. doi: 10.1056/NEJMoa062462.
    1. Kanis JA, Johnell O, Black DM, Downs RW, Jr, Sarkar S, Fuerst T, Secrest RJ, Pavo I. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone. 2003;33:293–300. doi: 10.1016/S8756-3282(03)00200-X.
    1. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010;47:729–735. doi: 10.1016/j.bone.2010.06.009.
    1. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–1934. doi: 10.1359/jbmr.080710.
    1. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2012;23:351–363. doi: 10.1007/s00198-011-1691-1.
    1. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:1049–1054. doi: 10.1016/j.bone.2009.02.014.
    1. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2011;22:567–576. doi: 10.1007/s00198-010-1302-6.
    1. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700–1707. doi: 10.1359/jbmr.1997.12.10.1700.
    1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541. doi: 10.1016/S0140-6736(96)07088-2.
    1. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9:1–160.
    1. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570–578. doi: 10.1210/er.2001-9002.
    1. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama. 1998;280:2077–2082. doi: 10.1001/jama.280.24.2077.
    1. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352. doi: 10.1001/jama.282.14.1344.
    1. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83–91. doi: 10.1007/s001980050010.
    1. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249. doi: 10.1359/JBMR.040325.
    1. Delmas PD, Recker RR, Chesnut CH, 3rd, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792–798. doi: 10.1007/s00198-004-1602-9.
    1. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237–245. doi: 10.1185/030079908X253717.
    1. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661. doi: 10.1136/ard.2005.044958.
    1. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838–1846. doi: 10.1002/art.21918.
    1. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653–661. doi: 10.1056/NEJMoa011807.
    1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822. doi: 10.1056/NEJMoa067312.
    1. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med. 2007;357:1–11. doi: 10.1056/NEJMoa074941.
    1. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011;89:91–104. doi: 10.1007/s00223-011-9499-8.
    1. Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010;25:2–10. doi: 10.1359/jbmr.091201.
    1. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657–663. doi: 10.1001/jama.2010.1098.
    1. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444. doi: 10.1136/bmj.c4444.
    1. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–2294. doi: 10.1002/jbmr.253.
    1. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG (2012) Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study. Osteoporos Int (in press)
    1. Hartle JE, Tang X, Kirchner HL, Bucaloiu ID, Sartorius JA, Pogrebnaya ZV, Akers GA, Carnero GE, Perkins RM. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2012;59:636–644. doi: 10.1053/j.ajkd.2011.11.037.
    1. Bondo L, Eiken P, Abrahamsen B (2012) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int (in press)
    1. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582–3590. doi: 10.1200/JCO.2010.28.2095.
    1. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22:373–390. doi: 10.1007/s00198-010-1453-5.
    1. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int. 2012;23:213–221. doi: 10.1007/s00198-011-1796-6.
    1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. doi: 10.1056/NEJM200105103441904.
    1. Shrader SP, Ragucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother. 2005;39:1511–1516. doi: 10.1345/aph.1G146.
    1. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20:1507–1513. doi: 10.1359/JBMR.050501.
    1. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459–468. doi: 10.1056/NEJMoa022436.
    1. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816–2822. doi: 10.1210/jc.2004-1774.
    1. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int. 2011;22:2347–2355. doi: 10.1007/s00198-010-1474-0.
    1. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012;23:1115–1122. doi: 10.1007/s00198-011-1847-z.
    1. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11:1–134.
    1. EMEA (2007) Questions and answers on the safety of Protelos/Osseor (strontium ranelate). European Medicines Agency. Accessed 24th January 2012
    1. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R, Reginster JY. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int. 2010;21:723–732. doi: 10.1007/s00198-009-1097-5.
    1. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353–356. doi: 10.1159/000069956.
    1. Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opin Pharmacother. 2011;12:2533–2552. doi: 10.1517/14656566.2011.618123.
    1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765. doi: 10.1056/NEJMoa0809493.
    1. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701. doi: 10.1002/jbmr.1479.
    1. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX(R). J Bone Miner Res Published online on Mar 19, 2012. doi:10.1002/jbmr.1606
    1. von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K, Goeree R, Tarride JE, Xie F. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum. 2011;41:178–186. doi: 10.1016/j.semarthrit.2011.03.005.
    1. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353:555–565. doi: 10.1056/NEJMoa050336.
    1. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS) J Bone Miner Res. 2009;24:726–736. doi: 10.1359/jbmr.081215.
    1. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122–128. doi: 10.1016/j.bone.2007.03.011.
    1. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93:852–860. doi: 10.1210/jc.2007-0711.
    1. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207–1215. doi: 10.1056/NEJMoa031975.
    1. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785–3793. doi: 10.1210/jc.2008-0353.
    1. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81. doi: 10.1359/jbmr.090716.
    1. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2012;23:295–303. doi: 10.1007/s00198-011-1547-8.
    1. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 2010;25:455–462. doi: 10.1359/jbmr.090821.
    1. Reginster JY. Effect of calcitonin on bone mass and fracture rates. Am J Med. 1991;91:19S–22S. doi: 10.1016/0002-9343(91)90242-P.
    1. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging. 1996;8:378–400. doi: 10.2165/00002512-199608050-00006.
    1. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:540–551. doi: 10.1210/er.2001-6002.
    1. Chesnut CH, 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267–276. doi: 10.1016/S0002-9343(00)00490-3.
    1. Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ. 1992;305:1124–1128. doi: 10.1136/bmj.305.6862.1124.
    1. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891–2897. doi: 10.1001/jama.285.22.2891.
    1. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Jama. 2003;290:1729–1738. doi: 10.1001/jama.290.13.1729.
    1. Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone. 2003;33:159–166. doi: 10.1016/S8756-3282(03)00171-6.
    1. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone. 2004;34:728–735. doi: 10.1016/j.bone.2003.12.021.
    1. Roussow JE, Anderson GL, Prentice RL, LaCroix A, Kooperberg C, Stefanick ML. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321.
    1. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. Jama. 2003;289:2673–2684. doi: 10.1001/jama.289.20.2673.
    1. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243–3253. doi: 10.1001/jama.289.24.3243.
    1. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651–2662. doi: 10.1001/jama.289.20.2651.
    1. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–1854. doi: 10.1056/NEJMoa030311.
    1. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701.
    1. Fenton A, Panay N. The Women's Health Initiative—a decade of progress. Climacteric. 2012;15:205. doi: 10.3109/13697137.2012.680255.
    1. Langer RD, Manson JE, Allison MA. Have we come full circle—or moved forward? The Women's Health Initiative 10 years on. Climacteric. 2012;15:206–212. doi: 10.3109/13697137.2012.666916.
    1. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73–79. doi: 10.1056/NEJM199007123230201.
    1. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15:301–310. doi: 10.1007/s00198-003-1570-5.
    1. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005;76:176–186. doi: 10.1007/s00223-004-0005-4.
    1. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992;326:357–362. doi: 10.1056/NEJM199202063260601.
    1. Gallagher JC, Rapuri PB, Smith LM. An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment. J Clin Endocrinol Metab. 2007;92:51–58. doi: 10.1210/jc.2006-1153.
    1. McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19:728–736. doi: 10.1359/jbmr.040116.
    1. McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22:135–141. doi: 10.1359/jbmr.061008.
    1. Boonen S, Van Meirhaeghe J, Bastian L, Cummings SR, Ranstam J, Tillman JB, Eastell R, Talmadge K, Wardlaw D. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res. 2011;26:1627–1637. doi: 10.1002/jbmr.364.
    1. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18:1311–1317. doi: 10.1007/s00198-007-0410-4.
    1. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414–2419. doi: 10.1001/archinte.165.20.2414.
    1. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13:394–401. doi: 10.1111/j.1524-4733.2009.00687.x.
    1. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811–818. doi: 10.1007/s00198-007-0506-x.
    1. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–581. doi: 10.1016/j.jval.2010.11.010.
    1. Strom O, Borgstrom F, Kanis JA, Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int. 2009;20:23–34. doi: 10.1007/s00198-008-0644-9.
    1. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011;22:2565–2573. doi: 10.1007/s00198-011-1668-0.
    1. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008. doi: 10.1007/s00198-004-1652-z.
    1. Rabenda V, Reginster JY. Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res. 2010;10:677–689. doi: 10.1586/erp.10.76.
    1. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17:1638–1644. doi: 10.1007/s00198-006-0166-2.
    1. Rabenda V, Bruyere O, Reginster JY. Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int. 2011;22:893–901. doi: 10.1007/s00198-010-1469-x.
    1. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586–1592. doi: 10.1210/jc.87.4.1586.
    1. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004;19:330–337. doi: 10.1359/JBMR.0301228.
    1. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–289. doi: 10.1016/S0002-9343(01)01124-X.
    1. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097–2104. doi: 10.1359/JBMR.050814.
    1. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1–10. doi: 10.1359/jbmr.2002.17.1.1.
    1. Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27:687–693. doi: 10.1002/jbmr.1472.
    1. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:1785–1790. doi: 10.1359/jbmr.060802.
    1. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92:3076–3081. doi: 10.1210/jc.2006-2758.
    1. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007;23:3041–3045. doi: 10.1185/030079907X242818.
    1. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW, Jr, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8:371–378. doi: 10.1385/JCD:8:4:371.
    1. Garnero P, Delmas PD. Biochemical markers of bone turnover in osteoporosis. In: Marcus M, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic; 2001. pp. 459–477.
    1. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84:2363–2368. doi: 10.1210/jc.84.7.2363.
    1. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:530–537. doi: 10.1002/jbmr.251.
    1. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001;12:922–930. doi: 10.1007/s001980170020.
    1. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051–1056. doi: 10.1359/jbmr.2003.18.6.1051.
    1. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006;22:61–66. doi: 10.1185/030079905X75096.
    1. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250–1258. doi: 10.1359/JBMR.040512.
    1. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone. 2008;42:832–836. doi: 10.1016/j.bone.2008.01.021.
    1. Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Lakartidningen. 2003;100:3436–3437.
    1. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–528. doi: 10.1111/j.1524-4733.2004.75003.x.
    1. Macroeconomics and health: investing in health for economic development: report of the Comission on Macroeconomics and Health. Geneva: WHO; 2001.
    1. Kanis JA, Jonsson B. Economic evaluation of interventions for osteoporosis. Osteoporos Int. 2002;13:765–767. doi: 10.1007/s001980200106.
    1. Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int. 2006;17:29–40. doi: 10.1007/s00198-005-1943-z.
    1. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int. 2007;18:9–23. doi: 10.1007/s00198-006-0257-0.
    1. Kanis JA, McCloskey E, Jonsson B, Cooper C, Strom B, Borgstrom F. An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos. 2010;5:19–48. doi: 10.1007/s11657-010-0045-5.
    1. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int. 2007;18:1047–1061. doi: 10.1007/s00198-007-0349-5.
    1. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12:417–427. doi: 10.1007/s001980170112.
    1. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int. 2006;17:1459–1471. doi: 10.1007/s00198-006-0107-0.
    1. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int. 2010;21:495–505. doi: 10.1007/s00198-009-0989-8.
    1. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int. 2010;21:339–349. doi: 10.1007/s00198-009-0971-5.
    1. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22:967–982. doi: 10.1007/s00198-010-1424-x.
    1. Update on pharmacological interventions and an algorithm for management. London: RCP; 2000.
    1. Delmas PD, Recker RR, Chesnut CH, 3rd, Skag A, Stakkestad JA, Emkey R et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–798

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다